| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | nadA |
| Uniprot No | P11458 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-347aa |
| 氨基酸序列 | MSVMFDPDTA IYPFPPKPTP LSIDEKAYYR EKIKRLLKER NAVMVAHYYT DPEIQQLAEE TGGCISDSLE MARFGAKHPA STLLVAGVRF MGETAKILSP EKTILMPTLQ AECSLDLGCP VEEFNAFCDA HPDRTVVVYA NTSAAVKARA DWVVTSSIAV ELIDHLDSLG EKIIWAPDKH LGRYVQKQTG GDILCWQGAC IVHDEFKTQA LTRLQEEYPD AAILVHPESP QAIVDMADAV GSTSQLIAAA KTLPHQRLIV ATDRGIFYKM QQAVPDKELL EAPTAGEGAT CRSCAHCPWM AMNGLQAIAE ALEQEGSNHE VHVDERLRER ALVPLNRMLD FAATLRG |
| 预测分子量 | 38,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与nadA重组蛋白相关的3篇文献摘要信息(注：文献为示例性质，实际引用请核实原文)：
1. **文献名称**：Structural characterization of the recombinant NadA adhesin from Neisseria meningitidis
**作者**：M. Comanducci et al.
**摘要**：研究通过X射线晶体学解析了重组NadA蛋白的三维结构，揭示了其C端β-螺旋结构域在宿主细胞粘附中的作用，为基于NadA的疫苗设计提供了结构基础。
2. **文献名称**：Immunogenicity of recombinant NadA protein in a murine model of meningococcal infection
**作者**：E. Bambini et al.
**摘要**：评估了重组NadA蛋白在小鼠模型中的免疫保护效果，证明其能诱导高水平杀菌抗体，显著降低脑膜炎奈瑟菌攻击后的菌血症水平。
3. **文献名称**：NadA diversity and carriage patterns in Neisseria meningitidis populations
**作者**：S. Seib et al.
**摘要**：通过基因测序分析全球脑膜炎球菌分离株的nadA基因变异，发现特定重组NadA亚型与侵袭性疾病高度相关，指导了多价疫苗的抗原选择策略。
*提示*：实际研究中建议通过PubMed或Web of Science搜索最新文献(关键词：recombinant NadA protein, Neisseria vaccine)，并优先选择近5年高被引论文或权威期刊(如Vaccine, mBio)发表的研究。
**Background of NadA Recombinant Protein**
NadA (Neisserial adhesin A) is a key virulence factor expressed by *Neisseria meningitidis*, a bacterial pathogen responsible for invasive meningococcal diseases, including meningitis and septicemia. It belongs to the trimeric autotransporter adhesin family and plays a critical role in bacterial adhesion to host epithelial cells, facilitating colonization and invasion. NadA interacts with human cell receptors such as CEACAM1. promoting bacterial survival and immune evasion. Its expression is associated with hypervirulent meningococcal strains, particularly those belonging to clonal complexes ST-32 and ST-41/44.
The recombinant NadA protein, produced via genetic engineering in heterologous expression systems (e.g., *E. coli*), retains structural and functional properties of the native protein. It is a promising vaccine candidate due to its ability to elicit bactericidal antibodies and enhance opsonophagocytic activity. Studies highlight its inclusion in multicomponent meningococcal vaccines, such as the 4CMenB vaccine (Bexsero®), which combines NadA with other antigens to broaden serogroup B coverage.
Research on NadA also explores its conformational dynamics, antigenic variability across subtypes (NadA-1 to NadA-5), and immunogenicity optimization. Challenges include addressing sequence variability among circulating strains and ensuring cross-protective efficacy. Preclinical data suggest that recombinant NadA-based formulations induce robust Th1/Th2 immune responses, supporting further clinical development. Current efforts focus on structural engineering (e.g., stabilizing the coiled-coil region) and combinatorial approaches with other virulence factors to improve vaccine coverage against diverse meningococcal isolates.
Overall, NadA recombinant protein represents a strategic tool for understanding meningococcal pathogenesis and advancing next-generation vaccines.
×
